BlackRock
OCUL icon

BlackRock’s Ocular Therapeutix OCUL Stock Holding History

BlackRock’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$190M Buy
19,376,555
+3,243,624
+20% +$29.4M ﹤0.01% 1827
2026
Q1 		$137M Buy
16,132,931
+530,537
+3% +$5.06M ﹤0.01% 1905
2025
Q4 		$189M Buy
15,602,394
+5,045,557
+48% +$61.3M ﹤0.01% 1714
2025
Q3 		$123M Buy
10,556,837
+10,458
+0.1% +$125K ﹤0.01% 1972
2025
Q2 		$97.9M Sell
10,546,379
-1,466,018
-12% -$11.5M ﹤0.01% 2062
2025
Q1 		$88.1M Buy
12,012,397
+165,910
+1% +$1.28M ﹤0.01% 2073
2024
Q4 		$101M Buy
11,846,487
+492,323
+4% +$4.8M ﹤0.01% 2077
2024
Q3 		$98.8M Sell
11,354,164
-166,162
-1% -$1.37M ﹤0.01% 2091
2024
Q2 		$78.8M Buy
11,520,326
+3,456,623
+43% +$21.3M ﹤0.01% 2170
2024
Q1 		$73.4M Buy
8,063,703
+2,302,170
+40% +$16.3M ﹤0.01% 2240
2023
Q4 		$25.7M Buy
5,761,533
+417,980
+8% +$1.24M ﹤0.01% 2865
2023
Q3 		$16.8M Buy
5,343,553
+80,633
+2% +$330K ﹤0.01% 3043
2023
Q2 		$27.2M Buy
5,262,920
+344,611
+7% +$2.05M ﹤0.01% 2844
2023
Q1 		$25.9M Sell
4,918,309
-34,428
-0.7% -$163K ﹤0.01% 2838
2022
Q4 		$13.9M Buy
4,952,737
+148,776
+3% +$493K ﹤0.01% 3222
2022
Q3 		$19.9M Buy
4,803,961
+8,358
+0.2% +$42.1K ﹤0.01% 3030
2022
Q2 		$19.3M Sell
4,795,603
-273,718
-5% -$1.03M ﹤0.01% 3110
2022
Q1 		$25.1M Sell
5,069,321
-53,514
-1% -$297K ﹤0.01% 3025
2021
Q4 		$35.7M Buy
5,122,835
+150,777
+3% +$1.17M ﹤0.01% 2902
2021
Q3 		$49.7M Sell
4,972,058
-7,554
-0.2% -$84.8K ﹤0.01% 2666
2021
Q2 		$70.6M Sell
4,979,612
-887,450
-15% -$13.5M ﹤0.01% 2469
2021
Q1 		$96.3M Buy
5,867,062
+354,798
+6% +$6.83M ﹤0.01% 2212
2020
Q4 		$114M Buy
5,512,264
+1,428,200
+35% +$21.2M ﹤0.01% 2010
2020
Q3 		$31.1M Buy
4,084,064
+466,439
+13% +$3.87M ﹤0.01% 2596
2020
Q2 		$30.1M Buy
3,617,625
+756,696
+26% +$5.02M ﹤0.01% 2574
2020
Q1 		$14.2M Buy
2,860,929
+31,285
+1% +$154K ﹤0.01% 2797
2019
Q4 		$11.2M Sell
2,829,644
-243,630
-8% -$847K ﹤0.01% 3193
2019
Q3 		$9.34M Buy
3,073,274
+132,529
+5% +$592K ﹤0.01% 3242
2019
Q2 		$12.9M Buy
2,940,745
+97,433
+3% +$361K ﹤0.01% 3095
2019
Q1 		$11.3M Buy
2,843,312
+50,560
+2% +$203K ﹤0.01% 3055
2018
Q4 		$11.1M Buy
2,792,752
+500,489
+22% +$2.76M ﹤0.01% 3024
2018
Q3 		$15.8M Buy
2,292,263
+326,381
+17% +$2.05M ﹤0.01% 2997
2018
Q2 		$13.3M Buy
1,965,882
+269,270
+16% +$1.85M ﹤0.01% 3095
2018
Q1 		$11M Buy
1,696,612
+278,035
+20% +$1.56M ﹤0.01% 3085
2017
Q4 		$6.31M Buy
1,418,577
+11,293
+0.8% +$57.7K ﹤0.01% 3353
2017
Q3 		$8.7M Buy
1,407,284
+27,184
+2% +$175K ﹤0.01% 3244
2017
Q2 		$12.8M Buy
1,380,100
+89,355
+7% +$865K ﹤0.01% 3030
2017
Q1 		$12M Buy
1,290,745
+1,288,196
+50,537% +$10.7M ﹤0.01% 3030
2016
Q4 		$22K Buy
2,549
+1,381
+118% +$10.7K ﹤0.01% 3229
2016
Q3 		$8K Hold
1,168
– – ﹤0.01% 3435
2016
Q2 		$6K Buy
1,168
+178
+18% +$1.76K ﹤0.01% 3490
2016
Q1 		$9K Buy
990
+668
+207% +$5.06K ﹤0.01% 3202
2015
Q4 		$3K Hold
322
– – ﹤0.01% 3261
2015
Q3 		$5K Hold
322
– – ﹤0.01% 3018
2015
Q2 		$7K Buy
+322
New +$7.98K ﹤0.01% 2993

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock's OCUL Position: Q2 2026 in Review

BlackRock increased its Ocular Therapeutix (OCUL) stake by 20% in Q2 2026, buying an estimated $29.4M and bringing the position to 19,376,555 shares worth $190M. The position accounts for ﹤0.01% of the portfolio, ranked #1827.

BlackRock first reported a position in OCUL in Q2 2015 and has held it in 45 quarters since. 261 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • BlackRock held 19,376,555 shares of Ocular Therapeutix worth $190M as of Q2 2026.
  • BlackRock bought 3,243,624 Ocular Therapeutix shares in Q2 2026, an estimated $29.4M.
  • Ocular Therapeutix made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #1827 holding.
  • BlackRock first reported a position in Ocular Therapeutix in Q2 2015 and has held it in 45 quarters since.
  • 261 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.